One case of severe hypomagnesemia induced by cetuximab
QI Chun-yan
QI Xiao-guang
Abstract：One 42-year-old male patient diagnosed as advanced metastasis of rectal cancer for 1 month was admitted. After admission, he received cetuximab injection (700 mg, ivgtt, d1;500 mg, ivgtt, d8, d15);irinotecan injection (120 mg, ivgtt, d1, d5);lfuorouracil injection (750 mg, d1;3500 mg pumped for 48 h, d1-2);calcium folinate injection (300 mg, ivgtt, d1). Severe hypomagnesaemia happened on the 19th day after treatment. The lowest serum magnesium during the treatment was 0.12 mmol·L-1 (normal reference range:0.7 –1.2 mmol·L-1). Considering the characteristics of each drug related adverse reaction, we inferred the hypomagnesemia may be associated with the use of cetuximab. After the treatment of large dose of magnesium supplementation, serum magnesium of the patient returned to normal after 13 days.
Keywords：CetuximabHypomagnesemiaAdverse drug reaction
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 131-132 )